Navigation Links
Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
Date:10/19/2009

SAN DIEGO, Calif., Oct. 19, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that new data from its obesity program will be presented at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society, to be held in Washington, D.C. October 24-28. Phase 2 data from the pramlintide/metreleptin combination treatment clinical program will be the subject of a late-breaking oral presentation. Obesity 2009 is one of the largest scientific conferences in the field of obesity.

Amylin will also present new scientific findings from preclinical studies related to its clinical-stage obesity programs for pramlintide/metreleptin and davalintide, an optimized amylin analog. These findings include new insights into the synergistic weight loss observed with various dual-hormone combination regimens. Additionally, Amylin will present at the meeting's pre-conference session focused on obesity pharmacotherapy.

"The discovery of leptin and its role, along with other endocrine signals, in regulating body weight through a neurohormonal feedback system marked the beginning of a new era of obesity research," said Christian Weyer, M.D., vice president, Medical Development at Amylin Pharmaceuticals. "Amylin's unique approach to obesity drug development aims to translate this evolving science into innovative new treatment options and builds on over 20 years of experience in peptide-protein therapeutics."

Key Amylin Activities at Obesity 2009:

Saturday, October 24

  • Pharmacotherapy Update invited presentation: Christian Weyer, M.D., vice president, Medical Development will present at this pre-conference session scheduled from 1:00 - 3:45 p.m. ET.

Sunday, October 25

  • Poster 190-P: "Central Mechanisms Underlying Am
    '/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014  UBM Medica US announces ... online community for oncologists, presents exclusive slide shows dealing ... essential to quality cancer care. Cancer ... ONCOLOGY , offers news, blogs, and podcasts about the ... quality cancer care: , End-of-life care is ...
(Date:7/31/2014)...  A substantial share of pharmacy and therapeutics ... are included in formularies—say patient support resources from ... Manhattan Research study, Taking the Pulse® Formulary ... P&T committee members in hospitals, managed care organizations ... a high bar for these programs, requiring that ...
(Date:7/31/2014)... , July 31, 2014 For its ... California , Art,s-Way Scientific has earned a ... With competition in over 30 categories, MBI,s contest ... MBI members, which include building manufacturers, dealers, and product ... an excellent example the capability of our team," said ...
Breaking Medicine Technology:Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 4
(Date:8/1/2014)... Oxford Gene Technology (OGT) is a ... include CytoSure heamatological cancer +SNP Array, CytoSure ISCA ... array, CytoSure ISCA sample tracking spike-ins and CytoSure ... as targeted sequencing services, SureSeq Solid Tumour Panel ... analysis, cytosure services and aCGH for CNV analysis. ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Roaming the ... preserved mummy became famous as the "Ice Man" no doubt ... of that may still not have shielded the Ice Man, ... A human,s genetic risk for atherosclerosis, or "hardening of the ... thousands of years ago, a new study finds. ...
(Date:8/1/2014)... LA The Health Resources and Services Administration ... Orleans School of Nursing an Advanced Nursing Education ... years. The funding will support training interprofessional teams ... for military veterans and diverse populations with behavioral ... DNP, CRNA, LSUHSC Nurse Anesthesia Program Director and ...
(Date:8/1/2014)... (GSA) the nation,s largest interdisciplinary organization devoted ... "Des" O,Neill, MA, MD, FRCPI, AGSF, FRCP(Glasg), FRCP, FRCP(Edin), ... the 2014 recipient of the Joseph T. Freeman Award. ... geriatrics and is awarded to a prominent physician in ... practice who is a member of the Society,s ...
(Date:8/1/2014)... 01, 2014 Lifeinsurancenomedicalexam.info has released ... insurance for clients who have high cholesterol levels. ... find and qualify for no medical exam life insurance. ... any background medical check-ups. , Since there are no ... level will qualify in just a few minutes. However, ...
Breaking Medicine News(10 mins):Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 3Health News:'Ice Man' Mummy May Have Been at Risk of Heart Disease 2Health News:LSUHSC Nursing awarded $1 million grant to improve care for veterans 2Health News:O'Neill to receive GSA's 2014 Joseph T. Freeman Award 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2
... in French . A team of ... have discovered a type of "cellular bilingualism" a ... different methods of communication to exchange information. "Our work ... function of dopaminergic, serotonergic and cholinergic neurons in diseases ...
... By Alan Mozes HealthDay Reporter , THURSDAY, March ... therapy may have gotten a little closer to reality, with ... hearts that were dangerously swollen after heart attacks. The ... bone marrow, then injecting them into the patient,s damaged heart. ...
... , WEDNESDAY, March 16 (HealthDay News) -- ... children participating in their school,s band, a new study ... high school band and found they were heavily contaminated ... which are associated with minor to serious infections and ...
... for the first time that stem cells injected into ... improved function to injured heart areas, according to a ... the American Heart Association . , Researchers said that ... findings are promising for the more than five million ...
... increasing frequency, parents of children with autism spectrum disorder ... their children wander or unexpectedly run away. One mother ... wandered away from her home, despite efforts to lock ... this problem, Autism Speaks, the world,s largest autism science ...
... -- Many American children who qualify for public health ... parents are confused about enrollment and eligibility, new research ... low-income households in Oregon and found that about 23 ... were not enrolled in the Oregon Health Plan (OHP), ...
Cached Medicine News:Health News:'Bilingual' neurons may reveal the secrets of brain disease 2Health News:Stem Cell Therapy Shrinks Enlarged Hearts 2Health News:Stem Cell Therapy Shrinks Enlarged Hearts 3Health News:Heart damage improves, reverses after stem cell injections in a preliminary human trial 2Health News:Autism Speaks supports new diagnostic code for individuals with autism with history of wandering 2Health News:Parents Often Confused About Kids' Health Coverage 2
Designed to insert eye spheres using spring loaded plunger. Polished finish. Overall length: 125 mm, 4.9 inches....
Size: Medium. 22.50 mm by 24.00 mm. Clear lucite. Supplied sterile....
... x 100 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
... x 80 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
Medicine Products: